Literature DB >> 2576207

Conformational changes induced by the transforming amino acid substitution in the transmembrane domain of the neu oncogene-encoded p185 protein.

P W Brandt-Rauf1, M R Pincus, J M Chen.   

Abstract

The neu oncogene is frequently found in certain types of human carcinomas and has been shown to be activated in animal models by nitrosourea-induced mutation. The activating mutation in the neu oncogene results in the substitution of a glutamic acid for a valine at position 664 in the transmembrane domain of the encoded protein product of 185 kda (designated p185), which, on the basis of homology studies, is presumed to be a receptor for an as yet unidentified growth factor. It has been proposed that activating amino acid substitutions in this region of p185 lead to a conformational change in the protein which causes signal transduction via an increase in tyrosine kinase activity in the absence of any external signal. Using conformational energy analysis, we have determined the preferred three-dimensional structures for the transmembrane decapeptide (residues 658-667) of the p185 protein with valine and glutamic acid at the critical position 664. The results indicate that the global minimum energy conformation of the decapeptide from the normal protein with Val at position 664 is an alpha-helix with a sharp bend (CD conformation at residues 664 and 665) in this region, whereas the global minimum conformation for the decapeptide from the mutant transforming protein with Glu at position 664 assumes an all alpha-helical configuration. Furthermore, the second highest energy conformation for the decapeptide from the normal protein is identical to the global minimum energy conformation for the decapeptide from the transforming protein, providing a possible explanation why overexpression of the normal protein also has a transforming effect.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2576207     DOI: 10.1007/bf01024899

Source DB:  PubMed          Journal:  J Protein Chem        ISSN: 0277-8033


  22 in total

1.  A point mutation in the neu oncogene mimics ligand induction of receptor aggregation.

Authors:  D B Weiner; J Liu; J A Cohen; W V Williams; M I Greene
Journal:  Nature       Date:  1989-05-18       Impact factor: 49.962

2.  Localization of a novel v-erbB-related gene, c-erbB-2, on human chromosome 17 and its amplification in a gastric cancer cell line.

Authors:  S Fukushige; K Matsubara; M Yoshida; M Sasaki; T Suzuki; K Semba; K Toyoshima; T Yamamoto
Journal:  Mol Cell Biol       Date:  1986-03       Impact factor: 4.272

3.  Neu receptor dimerization.

Authors:  M J Sternberg; W J Gullick
Journal:  Nature       Date:  1989-06-22       Impact factor: 49.962

4.  Protein structure and cancer.

Authors:  M R Pincus; P W Brandt-Rauf
Journal:  Cancer Invest       Date:  1986       Impact factor: 2.176

5.  Multiple independent activations of the neu oncogene by a point mutation altering the transmembrane domain of p185.

Authors:  C I Bargmann; M C Hung; R A Weinberg
Journal:  Cell       Date:  1986-06-06       Impact factor: 41.582

6.  Conformational analysis of the 20 naturally occurring amino acid residues using ECEPP.

Authors:  S S Zimmerman; M S Pottle; G Némethy; H A Scheraga
Journal:  Macromolecules       Date:  1977 Jan-Feb       Impact factor: 5.985

7.  Use of a symmetry condition to compute the conformation of gramicidin S1.

Authors:  M Dygert; N Gō; H A Scheraga
Journal:  Macromolecules       Date:  1975 Nov-Dec       Impact factor: 5.985

8.  Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene.

Authors:  D J Slamon; G M Clark; S G Wong; W J Levin; A Ullrich; W L McGuire
Journal:  Science       Date:  1987-01-09       Impact factor: 47.728

9.  erbB-2 is a potent oncogene when overexpressed in NIH/3T3 cells.

Authors:  P P Di Fiore; J H Pierce; M H Kraus; O Segatto; C R King; S A Aaronson
Journal:  Science       Date:  1987-07-10       Impact factor: 47.728

10.  Amplification of c-erbB-2 oncogene in human adenocarcinomas in vivo.

Authors:  J Yokota; T Yamamoto; K Toyoshima; M Terada; T Sugimura; H Battifora; M J Cline
Journal:  Lancet       Date:  1986-04-05       Impact factor: 79.321

View more
  7 in total

1.  Correlation of the structure of the transmembrane domain of the neu oncogene-encoded p185 protein with its function.

Authors:  P W Brandt-Rauf; S Rackovsky; M R Pincus
Journal:  Proc Natl Acad Sci U S A       Date:  1990-11       Impact factor: 11.205

2.  Bivalence of EGF-like ligands drives the ErbB signaling network.

Authors:  E Tzahar; R Pinkas-Kramarski; J D Moyer; L N Klapper; I Alroy; G Levkowitz; M Shelly; S Henis; M Eisenstein; B J Ratzkin; M Sela; G C Andrews; Y Yarden
Journal:  EMBO J       Date:  1997-08-15       Impact factor: 11.598

Review 3.  Oncogene proteins as biomarkers in the molecular epidemiology of occupational carcinogenesis. The example of the ras oncogene-encoded p21 protein.

Authors:  P W Brandt-Rauf
Journal:  Int Arch Occup Environ Health       Date:  1991       Impact factor: 3.015

4.  Conformation of the transmembrane domain of the epidermal growth factor receptor.

Authors:  P W Brandt-Rauf; R Monaco; M R Pincus
Journal:  J Protein Chem       Date:  1994-02

5.  Conformation of the transmembrane domain of the c-erbB-2 oncogene-encoded protein in its monomeric and dimeric states.

Authors:  P W Brandt-Rauf; M R Pincus; R Monaco
Journal:  J Protein Chem       Date:  1995-01

6.  Three dimensional structure of the transmembrane region of the proto-oncogenic and oncogenic forms of the neu protein.

Authors:  W J Gullick; A C Bottomley; F J Lofts; D G Doak; D Mulvey; R Newman; M J Crumpton; M J Sternberg; I D Campbell
Journal:  EMBO J       Date:  1992-01       Impact factor: 11.598

7.  A subdomain in the transmembrane domain is necessary for p185neu* activation.

Authors:  H Cao; L Bangalore; B J Bormann; D F Stern
Journal:  EMBO J       Date:  1992-03       Impact factor: 11.598

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.